Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetase

详细信息    查看全文

• 作者：Stephen Nakazawa Hewitt ; David M. Dranow ; Benjamin G. Horst ; Jan A. Abendroth ; Barbara Forte ; Irene Hallyburton ; Chimed Jansen ; Beatriz Baragaña ; Ryan Choi ; Kasey L. Rivas ; Matthew A. Hulverson ; Mitchell Dumais ; Thomas E. Edwards ; Donald D. Lorimer ; Alan H. Fairlamb ; David W. Gray ; Kevin D. Read ; Adele M. Lehane ; Kiaran Kirk ; Peter J. Myler ; Amy Wernimont ; Chris Walpole ; Robin Stacy ; Lynn K. Barrett ; Ian H. Gilbert ; Wesley C. Van Voorhis
• 刊名：ACS Infectious Diseases
• 出版年：2017
• 出版时间：January 13, 2017
• 年：2017
• 卷：3
• 期：1
• 页码：34-44
• 全文大小：858K
• ISSN：2373-8227

文摘

Plasmodium falciparum (Pf) prolyl-tRNA synthetase (ProRS) is one of the few chemical-genetically validated drug targets for malaria, yet highly selective inhibitors have not been described. In this paper, approximately 40,000 compounds were screened to identify compounds that selectively inhibit PfProRS enzyme activity versus Homo sapiens (Hs) ProRS. X-ray crystallography structures were solved for apo, as well as substrate- and inhibitor-bound forms of PfProRS. We identified two new inhibitors of PfProRS that bind outside the active site. These two allosteric inhibitors showed >100 times specificity for PfProRS compared to HsProRS, demonstrating this class of compounds could overcome the toxicity related to HsProRS inhibition by halofuginone and its analogues. Initial medicinal chemistry was performed on one of the two compounds, guided by the cocrystallography of the compound with PfProRS, and the results can instruct future medicinal chemistry work to optimize these promising new leads for drug development against malaria.